Evolus Announces Record Revenues With Botox Alternative - new Dermal Fillers Planned for GLP-1 Patients!

Evolus (EOLS) has the fastest growing neurotoxin for wrinkle treatment in the USA with Jeuveau, managing to increase its market share with the Botox alternative to 13%. It is used to treat glabellar lines (frown lines), and acceptance is rapidly increasing, particularly among younger women. Additionally, the loyalty program Evolus Reward grew by 40% last year to 1.1 million members, offering discounts for follow-up treatments. 220,000 redemptions alone in the fourth quarter contributed to a record figure and recurring revenue. A milestone was...